WHO ICTRP trial
Effect of dapagliflozin on nighttime blood pressure in type 2 diabetes
EUCTR2017-002125-38-ES · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2017-002125-38-ES |
|---|---|
| Public title | Effect of dapagliflozin on nighttime blood pressure in type 2 diabetes |
| Scientific title | Effect of dapagliflozin on nighttime blood pressure in type 2 diabetes |
| Primary sponsor | LM Diagnósticos S.L. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes |
| Countries | Spain |
| Conditions | Patients with diabetes and high blood pressure MedDRA version: 20.0 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C]… |
| Interventions | Trade Name: Forxiga 10 mg Product Name: Forxiga 10 mg Pharmaceutical Form: Film-coated tablet Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use |
| Registration date | Sep 17, 2018 |
| Target size | 225 |
| Secondary IDs | DAPA-ESR-16-12460 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: